Melbin Observational Research (MORE) Study of Metformin Therapy in Patients with Type 2 Diabetes Mellitus

  • Kaku Kohei
    Division of Diabetes and Endocrinology, Department of Medicine, Kawasaki Medical School
  • Tajima Naoko
    Division of Diabetes and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine
  • Kawamori Ryuzo
    Department of Medicine, Metabolism & Endocrinology, Juntendo University School of Medicine

Bibliographic Information

Other Title
  • 2型糖尿病治療におけるメトホルミンの使用実態に関する観察研究(MORE study)
  • 2型糖尿病におけるメトホルミン使用実態に関する観察研究(MORE Study)
  • 2ガタ トウニョウビョウ ニ オケル メトホルミン シヨウ ジッタイ ニ カンスル カンサツ ケンキュウ MORE Study

Search this article

Description

The Melbin observational research (MORE) study assessed the efficacy and safelty in Japanese type 2 diabetic patients treated with conventional metformin therapy. A total of 1,197 patients who received metformin therapy for the first time at 74 medical institutions, were enrolled in 2002. Mean HbA1C and fasting plasma glucose (FPG) values measured at 0, 3, 6 and 12 months of treatment. Mean HbA1C measured 8.2, 7.3, 7.3, and 7.3% and FPG 168.9, 146.6, 150.4, and 145.2 mg/dl, indicating significantly improved glycemic control during treatment. Body weight was significantly reduced, and no meaningful effect was observed on lipid metabolism. Similar effects were observed in patients treated with metformin alone. HbA1C improved significantly in 40 cases where the daily dose of metformin was increased from 500 mg to 750 mg. The incidence of adverse drug reactions was 10.0% (118/1,175 cases) and no lactic acidosis was observed. These results demonstrate a significant usefulness of current metformin therapy in Japanese type 2 diabetes mellitus. Results also suggest that an appropriate increment in the daily dose of metformin is required to obtain desirable HbA1C in patients whose glycemic control would otherwise not be acceptable.

Journal

Citations (7)*help

See more

References(14)*help

See more

Details 詳細情報について

Report a problem

Back to top